Page 125 - 2019_06-Haematologica-web

Obinutuzumab reduces POD24 risk in FL patients
and disease transformation.16,17 Interrogation of the GALLIUM dataset using m7-FLIPI and other potentially predictive indices is ongoing.
In conclusion, our results are consistent with previous studies that found a particularly poor outlook for patients with FL who suffer PD within 24 months of starting immunochemotherapy, and also further refine this obser-
vation by showing that there is a gradation of prognosis even within the POD24 subset, with earlier events pre- dicting more adverse outcomes. We observed that patients receiving G-based treatment have a much lower POD24 rate than those receiving R-based treatment; this supports the contention that more effective first-line treatment that reduces the POD24 rate may yield long-term benefit. Our
AB
CD
Figure 3. Landmark overall survival (OS) analysis, comparing patients with progressive disease or death due to progressive disease (POD) before the landmark and patients with noPOD. (A) 6-month, (B) 12-month, (C) 18-month, and (D) 24-month landmarks. The shaded sections of lines show 95% Hall-Wellner confidence bands for the period during which patients died. The table below the graph shows 2-year OS estimates (with 95%CI) at each landmark. N: number; CI: confidence interval; HR: hazard ratio.
haematologica | 2019; 104(6)
1207